Compare NVAX & BSTZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NVAX | BSTZ |
|---|---|---|
| Founded | 1987 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 1996 | N/A |
| Metric | NVAX | BSTZ |
|---|---|---|
| Price | $11.24 | $27.48 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $14.22 | N/A |
| AVG Volume (30 Days) | ★ 8.1M | 168.4K |
| Earning Date | 11-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.31% |
| EPS Growth | ★ 309.76 | N/A |
| EPS | N/A | ★ 0.71 |
| Revenue | ★ $1,123,479,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $39.31 |
| Revenue Growth | ★ 64.69 | N/A |
| 52 Week Low | $6.20 | $20.69 |
| 52 Week High | $13.39 | $31.89 |
| Indicator | NVAX | BSTZ |
|---|---|---|
| Relative Strength Index (RSI) | 50.30 | 32.41 |
| Support Level | $7.93 | $26.55 |
| Resistance Level | $11.73 | $31.59 |
| Average True Range (ATR) | 1.13 | 0.81 |
| MACD | 0.01 | -0.29 |
| Stochastic Oscillator | 28.62 | 6.40 |
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
BlackRock Science and Technology Trust II is a diversified, closed-end management investment company. Its investment objectives are to provide total return and income mainly through long-term capital appreciation. The Trust invests a majority of its total assets in equity securities issued by U.S. and non-U.S. science and technology companies in any market capitalization range, selected for their rapid and sustainable growth potential from the development, advancement, and use of science and/or technology. Its investment portfolio comprises securities of companies from various industries, such as semiconductors and semiconductor equipment, software, communications equipment, IT services, and entertainment, etc.